Marker Therapeutics Inc. (MRKR)
Symbol Info
Listed Symbol MRKR
Name Marker Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $205,994
Latest Fiscal EPS $-7.75
Price Info
21 Day Moving Average $4.9443
21 Day EMA $5.242240
50 Day Moving Average $6.3906
50 Day EMA $5.846720
200 Day EMA $6.148780
200 Day Moving Average 6.162580
52 Week High $10.60
52 Week Low $3.97
52 Week Change $-30.913600
Alpha 0.031502
Beta 0.1936
Standard Deviation 0.370760
R2 0.000328
Periods 60
Share Information
10 Day Average Volume 452,275
20 Day Average Volume 631,616
30 Day Average Volume 762,477
50 Day Average Volume 810,477
Outstanding Shares 45,670,597
Float Shares 30,458,457
Percent Float 66.69%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 99
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 1,181,490
Institute Holdings Percent 36.200000
Institute Sold Previous 3 Months 288,233
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months 29,040
Insider Holdings Percent 33.40%
Insider Sold Previous 3 Months -
Insiders Shares Owned 15,212,140
Price Change
7 Day Price Change $0.8600001
7 Day Percent Change 18.45%
21 Day Price Change $0.1500001
21 Day Percent Change 2.79%
30 Day Price Change $-3.48
30 Day Percent Change -38.67%
Month To Date Price Change $0.9100
Month To Date Percent 19.74%
90 Day Price Change $-0.23
90 Day Percent Change -4.00%
Quarter To Date $-2.4
Quarter To Date Percent -30.30%
180 Day Price Change $0.100000
180 Day Percent Change 1.85%
200 Day Price Change $-0.35
200 Day Percent Change -5.96%
Year To Date $-0.03
Year To Date Percent -0.54%
Profile
Description Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from our MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Details
Issue Type CS
Market Cap $252,101,695
Sec Type EQS
Auditor Marcum LLP
Total Shares Outstanding 45,670,597
CEO Peter L. Hoang
Employees 11
Last Audit UQ
Classification
CIK 0001094038
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 3200 Southwest Freeway
Suite 2240
Houston, TX 77027
Website http://www.markertherapeutics.com
Facisimile
Telephone +1 713 400-6400
Email investor.relations@markertherapeutics.com
Key Ratios
Profitability
EBIT Margin -73,115.1
EBITDA Margin -73,115.1
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $166,353,610
Price To Sales -
Price To Free Cash -12
PE High Last 5 Years -
Price To Book 4.3
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 4.3
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 16.9
Leverage Ratio 1.1
Quick Ratio 16.7
Long Term Debt To Capital 0.01
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -479.71
Return On Equity -543.09
Return On Capital -536.93
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
MRKR
Marker The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.